Director John B. Ketchum of Tango Therapeutics, Inc. filed a Form 4 on November 19, 2026, disclosing the sale of 3,333 shares of common stock on November 17, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: 3,333 shares of Tango Therapeutics common stock disposed of on November 17, 2026.
  • Weighted average price: $24.08 per share, with individual sale prices ranging from $24.08 to $25.0799 per share.
  • Trading plan: The sale was made under a Rule 10b5-1 trading plan adopted by Ketchum on August 18, 2026.
  • Remaining holdings: 21,604 shares beneficially owned following the transaction, held directly.
  • Unvested RSUs included: The post-transaction total includes 4,000 unvested Restricted Stock Units, each representing a contingent right to receive one share of common stock.

Ketchum's November 2026 Share Disposition Under 10b5-1 Plan

According to the filing, John B. Ketchum, a director of Tango Therapeutics, Inc. (NASDAQ:TNGX), sold 3,333 shares of the company's common stock on November 17, 2026. The filing indicates the transaction was effected pursuant to a Rule 10b5-1 trading plan that Ketchum adopted on August 18, 2026. The transaction is coded "S" in Table I of the Form 4, indicating a sale and disposal of securities.

The filing reports a weighted average sales price of $24.08 per share. According to the footnotes, the shares were sold at prices ranging from $24.08 to $25.0799 per share. The filing notes that "full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."

Following the reported transaction, Ketchum's direct beneficial ownership stands at 21,604 shares, according to the filing. The filing discloses that this total includes 4,000 unvested Restricted Stock Units. Each RSU, as stated in the filing, "represents a contingent right to receive one share of Common Stock of the Issuer." No derivative securities transactions were reported in Table II. The Form 4 was signed by Julie Fogarty as attorney-in-fact on November 19, 2026.

What Was Disclosed

Director John B. Ketchum disclosed the sale of 3,333 Tango Therapeutics common shares on November 17, 2026, at a weighted average price of $24.08, under a pre-established Rule 10b5-1 plan, leaving him with 21,604 shares beneficially owned directly.